Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 3 , Pages 403-414 , September 2007

The role of cofactors in sex steroid action

References 

  1. Brinkmann AO, Blok LJ, De Ruiter PE, et al. Mechanisms of androgen receptor activation and function. The Journal of Steroid Biochemistry and Molecular Biology. 1999;69:307–313
  2. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell. 2002;108:465–474
  3. Germain P, Staels B, Dacquet C, et al. Overview of nomenclature of nuclear receptors. Pharmacological Reviews. 2006;58:685–704
  4. McEwan IJ, Lavery D, Fischer K, et al. Natural disordered sequences in the amino terminal domain of nuclear receptors: lessons from the androgen and glucocorticoid receptors. Nuclear Receptor Signaling. 2007;5:e001
  5. Greschik H, Moras D. Structure-activity relationship of nuclear receptor-ligand interactions. Current Topics in Medicinal Chemistry. 2003;3:1573–1599
  6. Quigley CA, De Bellis A, Marschke KB, et al. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocrine Reviews. 1995;16:271–321
  7. Brinkmann AO. Molecular basis of androgen insensitivity. Molecular and Cellular Endocrinology. 2001;179:105–109
  8. Shaffer PL, Jivan A, Dollins DE, et al. Structural basis of androgen receptor binding to selective androgen response elements. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:4758–4763
  9. Matias PM, Donner P, Coelho R, et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor, implications for pathogenic mutations. The Journal of Biological Chemistry. 2000;275:26164–26171
  10. Sack JS, Kish KF, Wang C, et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural antagonist dihydrotestosterone. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:4904–4909
  11. Estebanez-Perpina , Moore JMR, Mar E, et al. The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. The Journal of Biological Chemistry. 2005;280:8060–8068
  12. Doesburg P, Kuil CW, Berrevoets CA, et al. Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry. 1997;36:1052–1064
  13. He B, Kemppainen JA, Wilson EM. FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. The Journal of Biological Chemistry. 2000;275:22986–22994
  14. Schaufele F, Carbonell X, Guerbadot , et al. The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxyl interactions. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:9802–9807
  15. Klokk TI, Kurys P, Elbi C, et al. Ligand-specific dynamics of the androgen receptor at its response element. Molecular and Cellular Biology. 2007;27:1823–1843
  16. Van Royen ME, Cunha SM, Brink MC, et al. Compartmentalization of androgen receptor protein–protein interactions in living cells. The Journal of Cell Biology. 2007;177:63–72
  17. He B, Gampe RT, Kole AJ, et al. Structural basis for androgen receptor interdomain interaction and coactivator interactions suggests a transition in nuclear activation function dominance. Molecular Cell. 2004;16:425–438
  18. Hur E, Pfaff SJ, Payne ES, et al. Recognition and accommodation at the androgen receptor coactivator binding interface. PloS Biolology. 2004;2:e274
  19. Li J, Zhang D, Fu J, et al. Structural and functional analysis of androgen receptor in chromatin. Molecular Endocrinology (in press), doi:10.1210/me.2006-0221 [Epub ahead of print].
  20. Zhou ZX, Lane MV, Kemppainen JA, et al. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Molecular Endocrinology. 1995;9:208–218
  21. Dubbink HJ, Hersmus R, Verma CS, et al. Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor. Molecular Endocrinology. 2004;18:2132–2150
  22. He B, Gampe RT, Hnat AT, et al. Probing the functional link between androgen receptor coactivator and ligand binding sites in prostate cancer and androgen insensitivity. The Journal of Biological Chemistry. 2006;281:6648–6663
  23. Rosenfeld MG, Lunyak VV, Glass CK. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes & Development. 2006;20:1405–1428
  24. Kouzarides T. Chromatin modifications and their function. Cell. 2007;128:693–705
  25. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell. 2007;128:707–719
  26. Hall JM, McDonnell DP. Coregulators in nuclear estrogen receptor action. Molecular Interventions. 2005;6:343–357
  27. Chen J, Kinyamu HK, Archer TK. Changes in attitude, changes in latitude: nuclear receptors remodelling chromatin to regulate transcription. Molecular Endocrinology. 2006;20:1–13
  28. Kornberg RD. Mediator and the mechanism of transcriptional activation. Trends in Biochemical Sciences. 2005;30:235–239
  29. Malik S, Roeder RG. Dynamic regulation of pol II transcription by the mammalian Mediator complex. Trends in Biochemical Sciences. 2005;30:256–263
  30. Belakavadi M, Fondell JD. Role of the mediator complex in nuclear hormone receptor signaling. Reviews of Physiology Biochemistry and Pharmacology. 2006;156:23–43
  31. Alen P, Claessens F, Verhoeven G, et al. The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Molecular and Cellular Biology. 1999;19:6085–6097
  32. Dubbink HJ, Hersmus R, Pike ACW, et al. Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping. Molecular Endocrinology. 2006;20:1742–1755
  33. He B, Minges JT, Lee LW, et al. The FXXLF motif mediates androgen receptor-specific interactions with coregulators. The Journal of Biological Chemistry. 2002;277:10226–10235
  34. Van de Wijngaart DJ, Van Royen ME, Hersmus R, et al. Novel FXXFF and FXXMF motifs in androgen receptor cofactors mediate high affinity and specific interactions with the ligand-binding domain. The Journal of Biological Chemistry. 2006;281:19407–19416
  35. Bai S, He B, Wilson EM. Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Molecular and Cellular Biology. 2005;25:1238–1257
  36. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocrine Reviews. 2002;23:175–200
  37. Link KA, Burd CJ, Williams E, et al. BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF. Molecular and Cellular Biology. 2005;25:2200–2215
  38. Domanskyi A, Virtanen KT, Palvimo JJ, et al. Biochemical characterization of androgen receptor-interacting protein 4. Biochemical Journal. 2006;393:789–795
  39. Wang Q, Sharma D, Ren Y, et al. A coregulatory role for the TRAP-Mediator complex in androgen receptor-mediated gene expression. The Journal of Biological Chemistry. 2002;277:42852–42858
  40. Coulthart VH, Matsuda S, Heery DM. An extended LXXLL motif sequence determines the nuclear receptor binding specificity of TRAP220. The Journal of Biological Chemistry. 2003;278:10942–10951
  41. McNally JG, Mueller WG, Walker D, et al. The glucocorticoid receptor: rapid exchange with regulatory sites. Science. 2000;287:1262–1265
  42. Farla P, Hersmus R, Geverts B, et al. The androgen receptor ligand-binding domain stabilizes DNA binding in living cells. Journal of Structural Biology. 2004;147:50–61
  43. Becker M, Baumann C, John S, et al. Dynamic behavior of transcription factors on a natural promoter in living cells. EMBO Reports. 2002;3:1188–1194
  44. Metivier R, Reid G, Gannon F. Transcription in four dimensions: Nuclear receptor-directed initiation of gene expression. EMBO Reports. 2006;7:1439–1446
  45. Adachi M, Takayanagi R, Tomura A, et al. Androgen-insensitivity syndrome as a possible coactivator disease. The New England Journal of Medicine. 2000;343:856–862
  46. Petrij F, Giles RH, Dauwerse HG, et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature. 1995;376:348–351
  47. Roberts CWM, Orkin SH. The SWI/SNF complex – chromatin and cancer. Nature Reviews. Cancer. 2004;4:133–142
  48. Anzick SL, Kononen J, Walker RL, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 1997;277:965–968

PII: S1521-690X(07)00057-7

doi: 10.1016/j.beem.2007.07.002

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 3 , Pages 403-414 , September 2007

Article Tools

* Image Usage & Resolution